Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.95B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 40 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EMLC | SYRE | |
|---|---|---|
Market Cap | $4.95B | $7.52B |
Volume | 2,930,860 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $108.92 |
52-Week Low | $24.53 | $22.18 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.92, up 0.24% on the day, but technical indicators signal a bearish trend with the stock recently hitting a 52-week low. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though some analysts see value in emerging market local currency bonds. Recent dividends of $0.14 and $0.13 were declared for October and August 2026.
Outlook remains cautious as dollar strength pressures emerging market currencies, though diversification benefits and yield potential offer long-term opportunities. Key risks include currency volatility and rising global bond yields, while institutional sentiment appears mixed with technical weakness dominating near-term price action.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
